Kyverna Therapeutics (KYTX) Cash & Equivalents (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Cash & Equivalents data on file, last reported at $28.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 49.53% year-over-year to $28.7 million; the trailing twelve-month figure through Mar 2026 stood at $28.7 million (down 49.53% YoY), and the FY2025 full-year result was $124.1 million, up 28.43% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $28.7 million, down from $124.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $224.3 million in Q1 2024 and bottomed at $23.0 million in Q3 2023.
• The 4-year median for Cash & Equivalents is $53.4 million (2023), against an average of $77.2 million.
• The widest annual swing landed in 2024, when Cash & Equivalents surged 463.73%; it then plunged 74.65% in 2025.
• A 4-year view of Cash & Equivalents shows it stood at $34.6 million in 2023, then soared by 178.87% to $96.6 million in 2024, then rose by 28.43% to $124.1 million in 2025, then slumped by 76.87% to $28.7 million in 2026.
• The last three Cash & Equivalents figures came in at $28.7 million (Q1 2026), $124.1 million (Q4 2025), and $34.2 million (Q3 2025), per Business Quant data.

Peer Comparison